Search published articles


Showing 4 results for Human Papilloma Virus
The prevalence of human papilloma virus(HPV)in malignant cervical lesion, using multiplex PCR
E. Keyhani, N. Kohannia, N. Izadimood, M. R. Keyhkhaee, H. Najmabadi,
Volume 64, Issue 3 (5-2006)
Abstract

Background: Cervical cancer is the second leading cause of cancer death among women. In this cancer, the effects of prevention, early diagnosis and treatment more than other cancers decrease the mortality rate. In 1970 human papilloma virus (HPV) was introduction as major etiologic factor of cervical cancer. Different studies throughout the world revealed strong correlation between HPV and cancerous & precancerous changes in epithelial cells. Since cell culture and serological methods can not recognize the virus and its subtypes, the importance of the molecular methods including polymerase chain reaction (PCR) in early and definite diagnosis of virus is obvious.

Methods: In this study, after patient selection using the related protocol and completion of the questionnaires, 100 samples from cancer lesions of cervix selected. Then DNA extraction from paraffin blocks performed using standard method. Multiplex PCR with two pairs of primer (one as internal control) performed and the PCR product run on 8% polyacrylamid gel.

Results: The results showed that 73% of the tissues were infected by HPV.

Conclusion: This finding confirm the previous results based of correlation between HPV,and cervical cancer.


HPV infection among patients with high grade cervical intraepithelial neoplasia and squamous cell carcinoma of cervix
Yarandi F, Izadi Mood N, Eftekhar Z, Niakan R, Tajziachi S,
Volume 65, Issue 14 (3-2008)
Abstract
Background: Cervical cancer is the second most common cancer of the women worldwide. It is also an important cause of cancer-related mortality in women, after breast cancer. Nearly half million of new cases are identified yearly. The incidence rate in developing countries is greater than the developed countries. Epidemiologic studies have shown that the association of genital human papilloma virus (HPV) with cervical cancer is strong, independent of other risk factors, and consistent in several countries. The aim of this study was to determine the frequency of HPV in patients with high grade cervical intraepithelial neoplasia (CINIII, CIN II) and squamous cell carcinoma (SCC) of cervix.
Methods: Hundred specimens from patients with SCC and CINIII, CIN II, confirmed by histological review, referring to Mirza Koochak Khan Hospital from 1999-2004 were enrolled in a cross sectional study. Polymerase chain reaction was utilized for identification and typing of HPV DNA. To increase the sensitivity of HPV detection, nested PCRs were performed using MY09/MY11 as outer and GP5/GP6 as inner primers.
Results: It was possible to extract 77 of 100 specimens that HPV DNA was detected in 47 of 77 specimens. Infection with HPV was present in 32 specimens (86.5%) among SCC patients and in 15 specimens (37.5%) among CINIII, CIN II patients. The most frequent HPV types in SCC patients were HPV 16 and 18 (59.38%) and then 33 (34.38%) and in CINIII, CIN II patients was 16 (53.33%) and 18 (40%). the most frequent co-infection in both groups was HPV 16 and 18 which was present in 40.62% and 26.7% of cases respectively.
Conclusions: The most frequent HPV types in patients with SCC and CINIII, CIN II was 16 and 18 that is identical to many other countries infection pattern.
Optimization the expression of human papilloma virus E6 and E7 polytopic construct in E. coli expression system
Arian Rahimi , Arash Arashkia , Amir Mirzaie , Hassan Noorbazargan , Seyed Ataollah Sadat Shandiz , Roghayeh Rahimi , Mehdi Mahdavi ,
Volume 73, Issue 9 (12-2015)
Abstract

Background: Human papilloma virus is a DNA virus from the papillomavirus family that is most prevalent in human cervical cancers and many studies showed the E6 and E7 proteins are present in the majority of cervical cancer cases. Development of universal HPV peptide-based vaccine with more serotypes coverage has considerable value. The aim of the study was to design a multi-epitope universal vaccine for major HPV based on E6 and E7 proteins and optimization the expression of polytopic construct contains E6 and E7 genes from different genotypes of human papilloma virus as a candid vaccine.

Methods: In this experimental study that was carried out in Pasteur Institute of Iran, Virology Department from October 2013 to November 2014. In order to design the polytypic construct, we predicted the most probable immunogenic epitopes of E6 and E7 from common high risk HPV16, 18, 31, 45 along with high prevalent type 6 and 11 using bioinformatics methods. The synthetic pET28a expression vector harboring E6 and E7 protein was transformed into Escherichia coli hosts and its expression was analyzed by SDS-PAGE and western blotting. Finally, in order to expression optimization of recombinant protein, cell density, induction time, growth temperature, IPTG (Isopropyl &beta-D-1-thiogalactopyranoside) concentration and cultures media were studied.

Results: In the present study the recombinant fusion protein was expressed successfully and the highest expression of target protein was achieved in super broth medium containing 0.1% glucose and 0.2% L-arabinose. In Super broth medium, the optimum condition for recombinant protein expression was occurred at OD600 of 0.8, 0.1mM IPTG, one hour’s incubation time at 37 °C and BL21 (A1) host.

Conclusion: The results of this study show that the optimum expression of E6 and E7 proteins from different genotypes of human papilloma virus can be performed. Moreover, by purification of recombinant protein and evaluation of its immunogenicity in mice, it can be used as a vaccine candidate against the human papilloma virus.


Evaluation of naloxone and alum adjuvants effect in HPV vaccine on immunoediting of mice in tumor microenvironment
Nazgol Malekzadeh , Faezeh Kabiri , Roghaye Ahangari ,
Volume 76, Issue 11 (2-2019)
Abstract
Background: Papilloma viruses are pathogenic double-strand DNA viruses that genotypes 16 and 18 are the cause of more than 50 percent of cancers as cervical cancer. Although vaccination is one of the best options for the papilloma cancer prevention but that is the most of world healthy problem, it is attempted to evaluate both naloxone (NLX) and alum mixture used as adjuvants together with HPV16 E7d vaccine to change the tumor microenvironment for the benefit of the immune system. The aim of this study was to investigate the effect of naloxone and alum mixture as adjuvants in HPV16 E7d vaccine on C57BL/6 female mouse in tumor microenvironment.
Methods: This study is a descriptive and cross-sectional study type, which was conducted on 80 case of C57BL/6 female mouse in Pasteur institute of Iran, Tehran over a period of six months in 2016. In this study, mice were vaccinated with dose of vaccine containing naloxone and alum mixture and alum as adjuvants and proper phosphate buffered saline (PBS) as control groups are considered. Tumor bearing mouse vaccinated by vaccine containing naloxone and alum mixture as adjuvants and phosphate buffered saline (PBS) as control group. Tumor model created through surgery and then tumor measurement done, the homogenate was created and protein concentration measured by Bradford system. Finally, assessment of IL-17, IL-4, IFN-γ and TGF-β cytokines concentration were performed by capture ELISA kit (mybiosource company) according to the company manual.
Results: It was observed that utilization of naloxone and alum mixture as adjuvant in the HPV16-E7d vaccine formulation significant reduction in the tumor growth (P≤0.0001) and reinforced meaningfully the cellular immunity reaction in tumor microenvironment.
Conclusion: The results of our study show that vaccine formulated with the naloxone and alum mixture as adjuvant in the HPV16-E7d vaccine increase the cellular immunity reaction on C57BL/6 female mouse in tumor microenvironment compared to phosphate buffered saline (PBS) control group in this new formulation as a papilloma viruses vaccine on C57BL/6 female mouse.

Page 1 from 1     

© 2026 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb